Europe Cancer Immunotherapy Market - Industry Trends and Forecast to 2033

List of Tables

The Europe cancer immunotherapy market is expected to reach USD 49,512.88 million by 2031 from USD 18,921.43 million in 2023, growing at a CAGR of 13.7% during the forecast period of 2024 to 2031.

Market Segmentation

Europe Cancer Immunotherapy Market, By Product Type (Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators, and Oncolytic Virus), Application (Lung Cancer, Breast Cancer, Melanoma, Myeloma, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Stomach Cancer, Colorectal Cancer, Head & Neck Cancer, and Others), End User (Hospitals, Oncology Clinics, Homecare, and Others), Form (Intravenous (IV), Intramuscular, and Oral), Distribution Channel (Direct Tenders, Retail Sales, and Pharmacies), Country (Germany, France, U.K., Italy, Russia, Spain, Turkey, Belgium, Netherlands, Switzerland, Denmark, and Rest of Europe) - Industry Trends and Forecast to 2031.

Overview of Europe Cancer Immunotherapy Market Dynamics

Driver
Rising prevalence of cancer incidences
Restraint
Increasing occurrence of immune-related adverse events
Opportunity
Growing trend towards combination therapies

Market Players

Some of the major market players operating in the Europe cancer immunotherapy market are:

Merck & Co., Inc.
F. Hoffmann-La Roche Ltd
Bristol-Myers Squibb Company
Janssen Pharmaceutical
AstraZeneca
Gilead Sciences, Inc.
Eli Lilly and Company
Amgen Inc.
Novartis AG
GSK
Pfizer Inc.
Incyte

1 INTRODUCTION 83

1.1 OBJECTIVES OF THE STUDY 83
1.2 MARKET DEFINITION 83
1.3 OVERVIEW OF THE EUROPE CANCER IMMUNOTHERAPY MARKET 83
1.4 CURRENCY AND PRICING 85
1.5 LIMITATIONS 85
1.6 MARKETS COVERED 85

2 MARKET SEGMENTATION 89

2.1 MARKETS COVERED 89
2.2 GEOGRAPHICAL SCOPE 90
2.3 YEARS CONSIDERED FOR THE STUDY 91
2.4 DBMR TRIPOD DATA VALIDATION MODEL 92
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 95
2.6 MULTIVARIATE MODELLING 96
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 96
2.8 MARKET END USER COVERAGE GRID 97
2.9 DBMR MARKET POSITION GRID 98
2.10 VENDOR SHARE ANALYSIS 99
2.11 SECONDARY SOURCES 100
2.12 ASSUMPTIONS 100

3 EXECUTIVE SUMMARY 101

4 PREMIUM INSIGHTS 103

4.1 PESTAL ANALYSIS 104
4.2 PORTERS 5 FORCES 105

5 EUROPE CANCER IMMUNOTHERAPY MARKET: REGULATIONS 106

6 MARKET OVERVIEW 114

6.1 DRIVERS 116
- 6.1.1 RISING PREVALENCE OF CANCER INCIDENCES 116
- 6.1.2 RISING TECHNOLOGICAL ADVANCEMENTS 116
- 6.1.3 INCREASED UNDERSTANDING OF TUMOR MICROENVIRONMENT 117
- 6.1.4 RISE IN PATIENT AWARENESS AND DEMAND FOR TARGETED TREATMENT 117
6.2 RESTRAINTS 118
- 6.2.1 INCREASING OCCURRENCE OF IMMUNE-RELATED ADVERSE EVENTS 118
- 6.2.2 DEVELOPING RESISTANCE TO CANCER TREATMENT 118
6.3 OPPORTUNITIES 119
- 6.3.1 GROWING TREND TOWARDS COMBINATION THERAPIES 119
- 6.3.2 RISING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND DIGITAL HEALTH TOOLS 119
- 6.3.3 DEVELOPMENT OF NEXT-GENERATION IMMUNOTHERAPIES 120
6.4 CHALLENGES 121
- 6.4.1 LACK OF STANDARDIZATION IN BIOMARKER TESTING 121
- 6.4.2 COMPLEXITY OF DEVELOPING AND IMPLEMENTING PERSONALIZED MEDICINE 121

7 EUROPE CANCER IMMUNOTHERAPY MARKET , BY PRODUCT TYPE 122

7.1 OVERVIEW 123
7.2 CHECKPOINT INHIBITORS 126
- 7.2.1 PROGRAMMED DEATH 1 (PD-1) & PROGRAMMED DEATH LIGAND 1 (PD-L1) 127
- 7.2.2 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4) 127
7.3 MONOCLONAL ANTIBODIES 128
- 7.3.1 NAKED MONOCLONAL ANTIBODIES 129
- 7.3.2 CONJUGATED MONOCLONAL ANTIBODIES 129
- 7.3.3 BISPECIFIC MONOCLONAL ANTIBODIES 129
7.4 VACCINES 130
- 7.4.1 PROPHYLACTIC VACCINES 131
- 7.4.2 THERAPEUTIC VACCINES 131
7.5 CELL THERAPIES 131
- 7.5.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY 132
- 7.5.2 T CELL THERAPY 132
7.6 IMMUNOMODULATORS 132
- 7.6.1 INTERFERONS 133
- 7.6.2 INTERLEUKINS 133
- 7.6.3 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR 133
7.7 ONCOLYTIC VIRUS 134

8 EUROPE CANCER IMMUNOTHERAPY MARKET , BY END USER 135

8.1 OVERVIEW 136
8.2 HOSPITALS 139
8.3 ONCOLOGY CLINICS 140
8.4 HOMECARE 140
8.5 OTHERS 141

9 EUROPE CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL 142

9.1 OVERVIEW 143
9.2 DIRECT TENDERS 146
9.3 RETAIL SALES 147
9.4 PHARMACIES 147
- 9.4.1 HOSPITAL 148
- 9.4.2 RETAIL 148
- 9.4.3 ONLINE 148

10 EUROPE CANCER IMMUNOTHERAPY MARKET, BY FORM 149

10.1 OVERVIEW 150
10.2 INTRAVENOUS (IV) 153
10.3 INTRAMUSCULAR 154
10.4 ORAL 154

11 EUROPE CANCER IMMUNOTHERAPY MARKET, BY APPLICATION 155

11.1 OVERVIEW 156
11.2 LUNG CANCER 159
- 11.2.1 CHECKPOINT INHIBITORS 160
- 11.2.2 MONOCLONAL ANTIBODIES 160
- 11.2.3 CELL THERAPIES 160
- 11.2.4 IMMUNOMODULATORS 160
11.3 BREAST CANCER 161
- 11.3.1 CHECKPOINT INHIBITORS 161
- 11.3.2 MONOCLONAL ANTIBODIES 161
- 11.3.3 CELL THERAPIES 162
- 11.3.4 IMMUNOMODULATORS 162
11.4 MELANOMA 162
- 11.4.1 CHECKPOINT INHIBITORS 163
- 11.4.2 MONOCLONAL ANTIBODIES 163
- 11.4.3 CELL THERAPIES 163
- 11.4.4 IMMUNOMODULATORS 163
- 11.4.5 ONCOLYTIC VIRUS 163
11.5 MULTIPLE MYELOMA 164
- 11.5.1 CHECKPOINT INHIBITORS 164
- 11.5.2 MONOCLONAL ANTIBODIES 164
- 11.5.3 CELL THERAPIES 164
- 11.5.4 IMMUNOMODULATORS 165
11.6 PROSTATE CANCER 165
- 11.6.1 CHECKPOINT INHIBITORS 165
- 11.6.2 MONOCLONAL ANTIBODIES 166
- 11.6.3 CELL THERAPIES 166
- 11.6.4 IMMUNOMODULATORS 166
- 11.6.5 VACCINES 166
11.7 OVARIAN CANCER 166
- 11.7.1 CHECKPOINT INHIBITORS 167
- 11.7.2 MONOCLONAL ANTIBODIES 167
- 11.7.3 CELL THERAPIES 167
- 11.7.4 IMMUNOMODULATORS 167
11.8 CERVICAL CANCER 168
- 11.8.1 CHECKPOINT INHIBITORS 168
- 11.8.2 MONOCLONAL ANTIBODIES 168
- 11.8.3 VACCINES 169
- 11.8.4 CELL THERAPIES 169
- 11.8.5 IMMUNOMODULATORS 169
11.9 STOMACH CANCER 169
- 11.9.1 CHECKPOINT INHIBITORS 170
- 11.9.2 MONOCLONAL ANTIBODIES 170
- 11.9.3 CELL THERAPIES 170
- 11.9.4 IMMUNOMODULATORS 170
11.10 COLORECTAL CANCER 170
- 11.10.1 CHECKPOINT INHIBITORS 171
- 11.10.2 MONOCLONAL ANTIBODIES 171
- 11.10.3 CELL THERAPIES 171
- 11.10.4 IMMUNOMODULATORS 171
11.11 HEAD AND NECK CANCER 172
- 11.11.1 CHECKPOINT INHIBITORS 172
- 11.11.2 MONOCLONAL ANTIBODIES 172
- 11.11.3 CELL THERAPIES 172
- 11.11.4 IMMUNOMODULATORS 173
11.12 OTHERS 173
- 11.12.1 CHECKPOINT INHIBITORS 173
- 11.12.2 MONOCLONAL ANTIBODIES 173
- 11.12.3 VACCINES 174
- 11.12.4 CELL THERAPIES 174
- 11.12.5 IMMUNOMODULATORS 174

12 EUROPE CANCER IMMUNOTHERAPY MARKET, BY REGION 175

12.1 EUROPE 177
- 12.1.1 GERMANY 185
- 12.1.2 FRANCE 193
- 12.1.3 ITALY 201
- 12.1.4 SPAIN 209
- 12.1.5 U.K. 217
- 12.1.6 SWITZERLAND 225
- 12.1.7 NETHERLANDS 233
- 12.1.8 RUSSIA 241
- 12.1.9 TURKEY 249
- 12.1.10 POLAND 257
- 12.1.11 HUNGARY 265
- 12.1.12 LITHUANIA 273
- 12.1.13 AUSTRIA 281
- 12.1.14 IRELAND 289
- 12.1.15 NORWAY 297
- 12.1.16 REST OF EUROPE 305

13 EUROPE CANCER IMMUNOTHERAPY MARKET, COMPANY LANDSCAPE 306

13.1 COMPANY SHARE ANALYSIS: EUROPE

14 SWOT ANALYSIS 307

15 COMPANY PROFILES 308

15.1 MERCK & CO., INC. 308
- 15.1.1 COMPANY SNAPSHOT 308
- 15.1.2 REVENUE ANALYSIS 308
- 15.1.3 COMPANY SHARE ANALYSIS 309
- 15.1.4 PRODUCT PORTFOLIO 309
- 15.1.5 RECENT DEVELOPMENTS 309
15.2 F. HOFFMANN-LA ROCHE LTD 310
- 15.2.1 COMPANY SNAPSHOT 310
- 15.2.2 REVENUE ANALYSIS 310
- 15.2.3 COMPANY SHARE ANALYSIS 311
- 15.2.4 PRODUCT PORTFOLIO 311
- 15.2.5 RECENT DEVELOPMENTS 311
15.3 BRISTOL-MYERS SQUIBB COMPANY 313
- 15.3.1 COMPANY SNAPSHOT 313
- 15.3.2 REVENUE ANALYSIS 313
- 15.3.3 COMPANY SHARE ANALYSIS 314
- 15.3.4 PRODUCT PORTFOLIO 314
- 15.3.5 RECENT DEVELOPMENTS 315
15.4 JANSSEN EUROPE SERVICES, LLC 316
- 15.4.1 COMPANY SNAPSHOT 316
- 15.4.2 REVENUE ANALYSIS 316
- 15.4.3 COMPANY SHARE ANALYSIS 317
- 15.4.4 PRODUCT PORTFOLIO 317
- 15.4.5 RECENT DEVELOPMENTS 318
15.5 ASTRAZENECA 319
- 15.5.1 COMPANY SNAPSHOT 319
- 15.5.2 REVENUE ANALYSIS 319
- 15.5.3 COMPANY SHARE ANALYSIS 320
- 15.5.4 PRODUCT PORTFOLIO 320
- 15.5.5 RECENT DEVELOPMENTS 321
15.6 ABBVIE INC. 322
- 15.6.1 COMPANY SNAPSHOT 322
- 15.6.2 PIPELINE PORTFOLIO 322
- 15.6.3 RECENT DEVELOPMENTS 322
15.7 AMGEN INC. 323
- 15.7.1 COMPANY SNAPSHOT 323
- 15.7.2 REVENUE ANALYSIS 324
- 15.7.3 PIPELINE PORTFOLIO 324
- 15.7.4 PRODUCT PORTFOLIO 325
- 15.7.5 RECENT DEVELOPMENTS 325
15.8 ATARA BIOTHERAPEUTICS, INC. 326
- 15.8.1 COMPANY SNAPSHOT 326
- 15.8.2 PIPELINE PORTFOLIO 326
- 15.8.3 RECENT DEVELOPMENTS 326
15.9 BAYER AG 327
- 15.9.1 COMPANY SNAPSHOT 327
- 15.9.2 PIPELINE PORTFOLIO 327
- 15.9.3 RECENT DEVELOPMENTS 327
15.10 CELLDEX THERAPEUTICS. 329
- 15.10.1 COMPANY SNAPSHOT 329
- 15.10.2 PIPELINE PORTFOLIO 329
- 15.10.3 RECENT DEVELOPMENTS 329
15.11 CELLECTIS 330
- 15.11.1 COMPANY SNAPSHOT 330
- 15.11.2 PIPELINE PORTFOLIO 330
- 15.11.3 RECENT DEVELOPMENTS 330
15.12 GILEAD SCIENCES, INC. 331
- 15.12.1 COMPANY SNAPSHOT 331
- 15.12.2 REVENUE ANALYSIS 331
- 15.12.3 PRODUCT PORTFOLIO 332
- 15.12.4 RECENT DEVELOPMENTS 332
15.13 GSK PLC. 333
- 15.13.1 COMPANY SNAPSHOT 333
- 15.13.2 REVENUE ANALYSIS 333
- 15.13.3 PRODUCT PORTFOLIO 334
- 15.13.4 RECENT DEVELOPMENTS 334
15.14 INCYTE. 335
- 15.14.1 COMPANY SNAPSHOT 335
- 15.14.2 REVENUE ANALYSIS 335
- 15.14.3 PRODUCT PORTFOLIO 336
- 15.14.4 RECENT DEVELOPMENTS 336
15.15 LILLY. 337
- 15.15.1 COMPANY SNAPSHOT 337
- 15.15.2 REVENUE ANALYSIS 338
- 15.15.3 PRODUCT PORTFOLIO 338
- 15.15.4 RECENT DEVELOPMENTS 339
15.16 NOVARTIS AG 340
- 15.16.1 COMPANY SNAPSHOT 340
- 15.16.2 REVENUE ANALYSIS 340
- 15.16.3 PIPELINE PORTFOLIO 341
- 15.16.4 PRODUCT PORTFOLIO 341
- 15.16.5 RECENT DEVELOPMENTS 341
15.17 PFIZER INC. 342
- 15.17.1 COMPANY SNAPSHOT 342
- 15.17.2 REVENUE ANALYSIS 342
- 15.17.3 PRODUCT PORTFOLIO 343
- 15.17.4 RECENT DEVELOPMENTS 343

16 QUESTIONNAIRE 344

17 RELATED REPORTS 348

LIST OF TABLES

TABLE 1 EUROPE CANCER IMMUNOTHERAPY MARKET , BY PRODUCT TYPE, 2022- 2031 (USD MILLION) 82
TABLE 2 EUROPE CHECKPOINT INHIBITORS CANCER IMMUNOTHERAPY IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 82
TABLE 3 EUROPE CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET , BY TYPE, 2022- 2031 (USD MILLION) 83
TABLE 4 EUROPE CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET , BY TYPE, 2022- 2031 (UNITS) 83
TABLE 5 EUROPE MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 84
TABLE 6 EUROPE MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET , BY TYPE, 2022- 2031 (USD MILLION) 84
TABLE 7 EUROPE MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET , BY TYPE, 2022- 2031 (UNITS) 85
TABLE 8 EUROPE VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 86
TABLE 9 EUROPE VACCINES IN CANCER IMMUNOTHERAPY MARKET , BY TYPE, 2022- 2031 (USD MILLION) 86
TABLE 10 EUROPE VACCINES IN CANCER IMMUNOTHERAPY MARKET , BY TYPE, 2022- 2031 (UNITS) 86
TABLE 11 EUROPE CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 87
TABLE 12 EUROPE CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET , BY TYPE, 2022- 2031 (USD MILLION) 87
TABLE 13 EUROPE CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET , BY TYPE, 2022- 2031 (UNITS) 88
TABLE 14 EUROPE IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 88
TABLE 15 EUROPE IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET , BY TYPE, 2022- 2031 (USD MILLION) 89
TABLE 16 EUROPE IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 89
TABLE 17 EUROPE ONCOLYTIC VIRUS IN CANCER IMMUNOTHERAPYMARKET, BY REGION, 2022-2031 (USD MILLION) 90
TABLE 18 EUROPE CANCER IMMUNOTHERAPY MARKET , BY END USER, 2022- 2031 (USD MILLION) 95
TABLE 19 EUROPE HOSPITALS IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 95
TABLE 20 EUROPE ONCOLOGY CLINICS IN CANCER IMMUNOTHERAPY IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 96
TABLE 21 EUROPE HOMECARE IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 96
TABLE 22 EUROPE OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 97
TABLE 23 EUROPE CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 102
TABLE 24 EUROPE DIRECT TENDERS IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 102
TABLE 25 EUROPE RETAIL SALES IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 103
TABLE 26 EUROPE PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 103
TABLE 27 EUROPE PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 104
TABLE 28 EUROPE CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 109
TABLE 29 EUROPE INTRAVENOUS IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 109
TABLE 30 EUROPE INTRAMUSCULAR IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 110
TABLE 31 EUROPE ORAL IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 110
TABLE 32 EUROPE CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 115
TABLE 33 EUROPE LUNG CANCERI N CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 115
TABLE 34 EUROPE LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 116
TABLE 35 EUROPE BREAST CANCERI N CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 117
TABLE 36 EUROPE BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 117
TABLE 37 EUROPE MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 118
TABLE 38 EUROPE MELANOMA CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 118
TABLE 39 EUROPE MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 120
TABLE 40 EUROPE MULTIPLE MYELOMA CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 120
TABLE 41 EUROPE PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 121
TABLE 42 EUROPE PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 121
TABLE 43 EUROPE OVARIANC ANCER IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 122
TABLE 44 EUROPE OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 123
TABLE 45 EUROPE CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 124
TABLE 46 EUROPE CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 124
TABLE 47 EUROPE STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 125
TABLE 48 EUROPE STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 125
TABLE 49 EUROPE COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 126
TABLE 50 EUROPE COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 127
TABLE 51 EUROPE HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 128
TABLE 52 EUROPE HEAD & NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 128
TABLE 53 EUROPE OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 129
TABLE 54 EUROPE OTHERS CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 129
TABLE 55 EUROPE CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 133
TABLE 56 EUROPE CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 133
TABLE 57 EUROPE CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 134
TABLE 58 EUROPE CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 134
TABLE 59 EUROPE MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 134
TABLE 60 EUROPE MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 134
TABLE 61 EUROPE VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 135
TABLE 62 EUROPE VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 135
TABLE 63 EUROPE CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 135
TABLE 64 EUROPE CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 135
TABLE 65 EUROPE IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 135
TABLE 66 EUROPE IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 136
TABLE 67 EUROPE CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 136
TABLE 68 EUROPE LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 136
TABLE 69 EUROPE BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 137
TABLE 70 EUROPE MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 137
TABLE 71 EUROPE MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 137
TABLE 72 EUROPE PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 137
TABLE 73 EUROPE OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 138
TABLE 74 EUROPE CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 138
TABLE 75 EUROPE STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 138
TABLE 76 EUROPE COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 138
TABLE 77 EUROPE HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 139
TABLE 78 EUROPE OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 139
TABLE 79 EUROPE CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 139
TABLE 80 EUROPE CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 139
TABLE 81 EUROPE CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 140
TABLE 82 EUROPE PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 140
TABLE 83 GERMANY CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 141
TABLE 84 GERMANY CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 141
TABLE 85 GERMANY CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 141
TABLE 86 GERMANY CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 141
TABLE 87 GERMANY MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 142
TABLE 88 GERMANY MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 142
TABLE 89 GERMANY MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 142
TABLE 90 GERMANY VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 142
TABLE 91 GERMANY VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 142
TABLE 92 GERMANY VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 143
TABLE 93 GERMANY CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 143
TABLE 94 GERMANY CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 143
TABLE 95 GERMANY CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 143
TABLE 96 GERMANY IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 143
TABLE 97 GERMANY IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 144
TABLE 98 GERMANY IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 144
TABLE 99 GERMANY CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 144
TABLE 100 GERMANY LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 144
TABLE 101 GERMANY BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 145
TABLE 102 GERMANY MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 145
TABLE 103 GERMANY MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 145
TABLE 104 GERMANY PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 145
TABLE 105 GERMANY OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 146
TABLE 106 GERMANY CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 146
TABLE 107 GERMANY STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 146
TABLE 108 GERMANY COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 146
TABLE 109 GERMANY HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 147
TABLE 110 GERMANY OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 147
TABLE 111 GERMANY CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 147
TABLE 112 GERMANY CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 147
TABLE 113 GERMANY CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 148
TABLE 114 GERMANY PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 148
TABLE 115 FRANCE CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 149
TABLE 116 FRANCE CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 149
TABLE 117 FRANCE CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 149
TABLE 118 FRANCE CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 149
TABLE 119 FRANCE MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 150
TABLE 120 FRANCE MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 150
TABLE 121 FRANCE MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 150
TABLE 122 FRANCE VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 150
TABLE 123 FRANCE VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 150
TABLE 124 FRANCE VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 151
TABLE 125 FRANCE CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 151
TABLE 126 FRANCE CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 151
TABLE 127 FRANCE CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 151
TABLE 128 FRANCE IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 151
TABLE 129 FRANCE IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 152
TABLE 130 FRANCE IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 152
TABLE 131 FRANCE CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 152
TABLE 132 FRANCE LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 152
TABLE 133 FRANCE BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 153
TABLE 134 FRANCE MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 153
TABLE 135 FRANCE MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 153
TABLE 136 FRANCE PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 153
TABLE 137 FRANCE OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 154
TABLE 138 FRANCE CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 154
TABLE 139 FRANCE STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 154
TABLE 140 FRANCE COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 154
TABLE 141 FRANCE HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 155
TABLE 142 FRANCE OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 155
TABLE 143 FRANCE CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 155
TABLE 144 FRANCE CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 155
TABLE 145 FRANCE CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 156
TABLE 146 FRANCE PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 156
TABLE 147 ITALY CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 157
TABLE 148 ITALY CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 157
TABLE 149 ITALY CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 157
TABLE 150 ITALY CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 157
TABLE 151 ITALY MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 158
TABLE 152 ITALY MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 158
TABLE 153 ITALY MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 158
TABLE 154 ITALY VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 158
TABLE 155 ITALY VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 158
TABLE 156 ITALY VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 159
TABLE 157 ITALY CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 159
TABLE 158 ITALY CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 159
TABLE 159 ITALY CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 159
TABLE 160 ITALY IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 159
TABLE 161 ITALY IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 159
TABLE 162 ITALY IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 160
TABLE 163 ITALY CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 160
TABLE 164 ITALY LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 160
TABLE 165 ITALY BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 161
TABLE 166 ITALY MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 161
TABLE 167 ITALY MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 161
TABLE 168 ITALY PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 161
TABLE 169 ITALY OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 162
TABLE 170 ITALY CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 162
TABLE 171 ITALY STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 162
TABLE 172 ITALY COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 162
TABLE 173 ITALY HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 163
TABLE 174 ITALY OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 163
TABLE 175 ITALY CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 163
TABLE 176 ITALY CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 163
TABLE 177 ITALY CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 164
TABLE 178 ITALY PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 164
TABLE 179 SPAIN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 165
TABLE 180 SPAIN CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 165
TABLE 181 SPAIN CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 165
TABLE 182 SPAIN CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 165
TABLE 183 SPAIN MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 166
TABLE 184 SPAIN MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 166
TABLE 185 SPAIN MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 166
TABLE 186 SPAIN VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 166
TABLE 187 SPAIN VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 166
TABLE 188 SPAIN VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 167
TABLE 189 SPAIN CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 167
TABLE 190 SPAIN CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 167
TABLE 191 SPAIN CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 167
TABLE 192 SPAIN IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 167
TABLE 193 SPAIN IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 167
TABLE 194 SPAIN IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 168
TABLE 195 SPAIN CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 168
TABLE 196 SPAIN LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 168
TABLE 197 SPAIN BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 169
TABLE 198 SPAIN MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 169
TABLE 199 SPAIN MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 169
TABLE 200 SPAIN PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 169
TABLE 201 SPAIN OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 170
TABLE 202 SPAIN CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 170
TABLE 203 SPAIN STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 170
TABLE 204 SPAIN COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 170
TABLE 205 SPAIN HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 171
TABLE 206 SPAIN OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 171
TABLE 207 SPAIN CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 171
TABLE 208 SPAIN CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 171
TABLE 209 SPAIN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 172
TABLE 210 SPAIN PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 172
TABLE 211 U.K. CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 173
TABLE 212 U.K. CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 173
TABLE 213 U.K. CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 173
TABLE 214 U.K. CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 173
TABLE 215 U.K. MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 174
TABLE 216 U.K. MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 174
TABLE 217 U.K. MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 174
TABLE 218 U.K. VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 174
TABLE 219 U.K. VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 174
TABLE 220 U.K. VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 175
TABLE 221 U.K. CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 175
TABLE 222 U.K. CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 175
TABLE 223 U.K. CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 175
TABLE 224 U.K. IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 175
TABLE 225 U.K. IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 175
TABLE 226 U.K. IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 176
TABLE 227 U.K. CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 176
TABLE 228 U.K. LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 176
TABLE 229 U.K. BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 177
TABLE 230 U.K. MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 177
TABLE 231 U.K. MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 177
TABLE 232 U.K. PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 177
TABLE 233 U.K. OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 178
TABLE 234 U.K. CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 178
TABLE 235 U.K. STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 178
TABLE 236 U.K. COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 178
TABLE 237 U.K. HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 179
TABLE 238 U.K. OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 179
TABLE 239 U.K. CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 179
TABLE 240 U.K. CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 179
TABLE 241 U.K. CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 180
TABLE 242 U.K. PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 180
TABLE 243 SWITZERLAND CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 181
TABLE 244 SWITZERLAND CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 181
TABLE 245 SWITZERLAND CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 181
TABLE 246 SWITZERLAND CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 181
TABLE 247 SWITZERLAND MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 182
TABLE 248 SWITZERLAND MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 182
TABLE 249 SWITZERLAND MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 182
TABLE 250 SWITZERLAND VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 182

TABLE 251 SWITZERLAND VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 182
TABLE 252 SWITZERLAND VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 183
TABLE 253 SWITZERLAND CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 183
TABLE 254 SWITZERLAND CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 183
TABLE 255 SWITZERLAND CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 183
TABLE 256 SWITZERLAND IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 183
TABLE 257 SWITZERLAND IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 184
TABLE 258 SWITZERLAND IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 184
TABLE 259 SWITZERLAND CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 184
TABLE 260 SWITZERLAND LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 184
TABLE 261 SWITZERLAND BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 185
TABLE 262 SWITZERLAND MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 185
TABLE 263 SWITZERLAND MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 185
TABLE 264 SWITZERLAND PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 185
TABLE 265 SWITZERLAND OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 186
TABLE 266 SWITZERLAND CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 186
TABLE 267 SWITZERLAND STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 186
TABLE 268 SWITZERLAND COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 186
TABLE 269 SWITZERLAND HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 187
TABLE 270 SWITZERLAND OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 187
TABLE 271 SWITZERLAND CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 187
TABLE 272 SWITZERLAND CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 187
TABLE 273 SWITZERLAND CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 188
TABLE 274 SWITZERLAND PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 188
TABLE 275 NETHERLANDS CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 189
TABLE 276 NETHERLANDS CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 189
TABLE 277 NETHERLANDS CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 189
TABLE 278 NETHERLANDS CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 189
TABLE 279 NETHERLANDS MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 190
TABLE 280 NETHERLANDS MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 190
TABLE 281 NETHERLANDS MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 190
TABLE 282 NETHERLANDS VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 190
TABLE 283 NETHERLANDS VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 190
TABLE 284 NETHERLANDS VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 191
TABLE 285 NETHERLANDS CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 191
TABLE 286 NETHERLANDS CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 191
TABLE 287 NETHERLANDS CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 191
TABLE 288 NETHERLANDS IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 191
TABLE 289 NETHERLANDS IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 192
TABLE 290 NETHERLANDS IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 192
TABLE 291 NETHERLANDS CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 192
TABLE 292 NETHERLANDS LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 192
TABLE 293 NETHERLANDS BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 193
TABLE 294 NETHERLANDS MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 193
TABLE 295 NETHERLANDS MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 193
TABLE 296 NETHERLANDS PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 193
TABLE 297 NETHERLANDS OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 194
TABLE 298 NETHERLANDS CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 194
TABLE 299 NETHERLANDS STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 194
TABLE 300 NETHERLANDS COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 194
TABLE 301 NETHERLANDS HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 195
TABLE 302 NETHERLANDS OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 195
TABLE 303 NETHERLANDS CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 195
TABLE 304 NETHERLANDS CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 195
TABLE 305 NETHERLANDS CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 196
TABLE 306 NETHERLANDS PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 196
TABLE 307 RUSSIA CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 197
TABLE 308 RUSSIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 197
TABLE 309 RUSSIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 197
TABLE 310 RUSSIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 197
TABLE 311 RUSSIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 198
TABLE 312 RUSSIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 198
TABLE 313 RUSSIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 198
TABLE 314 RUSSIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 198
TABLE 315 RUSSIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 198
TABLE 316 RUSSIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 199
TABLE 317 RUSSIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 199
TABLE 318 RUSSIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 199
TABLE 319 RUSSIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 199
TABLE 320 RUSSIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 199
TABLE 321 RUSSIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 200
TABLE 322 RUSSIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 200
TABLE 323 RUSSIA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 200
TABLE 324 RUSSIA LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 200
TABLE 325 RUSSIA BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 201
TABLE 326 RUSSIA MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 201
TABLE 327 RUSSIA MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 201
TABLE 328 RUSSIA PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 201
TABLE 329 RUSSIA OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 202
TABLE 330 RUSSIA CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 202
TABLE 331 RUSSIA STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 202
TABLE 332 RUSSIA COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 202
TABLE 333 RUSSIA HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 203
TABLE 334 RUSSIA OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 203
TABLE 335 RUSSIA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 203
TABLE 336 RUSSIA CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 203
TABLE 337 RUSSIA CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 204
TABLE 338 RUSSIA PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 204
TABLE 339 TURKEY CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 205
TABLE 340 TURKEY CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 205
TABLE 341 TURKEY CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 205
TABLE 342 TURKEY CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 205
TABLE 343 TURKEY MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 206
TABLE 344 TURKEY MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 206
TABLE 345 TURKEY MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 206
TABLE 346 TURKEY VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 206
TABLE 347 TURKEY VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 206
TABLE 348 TURKEY VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 207
TABLE 349 TURKEY CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 207
TABLE 350 TURKEY CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 207
TABLE 351 TURKEY CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 207
TABLE 352 TURKEY IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 207
TABLE 353 TURKEY IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 208
TABLE 354 TURKEY IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 208
TABLE 355 TURKEY CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 208
TABLE 356 TURKEY LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 208
TABLE 357 TURKEY BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 209
TABLE 358 TURKEY MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 209
TABLE 359 TURKEY MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 209
TABLE 360 TURKEY PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 209
TABLE 361 TURKEY OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 210
TABLE 362 TURKEY CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 210
TABLE 363 TURKEY STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 210
TABLE 364 TURKEY COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 210
TABLE 365 TURKEY HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 211
TABLE 366 TURKEY OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 211
TABLE 367 TURKEY CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 211
TABLE 368 TURKEY CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 211
TABLE 369 TURKEY CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 212
TABLE 370 TURKEY PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 212
TABLE 371 POLAND CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 213
TABLE 372 POLAND CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 213
TABLE 373 POLAND CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 213
TABLE 374 POLAND CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 213
TABLE 375 POLAND MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 214
TABLE 376 POLAND MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 214
TABLE 377 POLAND MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 214
TABLE 378 POLAND VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 214
TABLE 379 POLAND VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 214
TABLE 380 POLAND VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 215
TABLE 381 POLAND CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 215
TABLE 382 POLAND CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 215
TABLE 383 POLAND CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 215
TABLE 384 POLAND IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 215
TABLE 385 POLAND IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 216
TABLE 386 POLAND IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 216
TABLE 387 POLAND CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 216
TABLE 388 POLAND LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 216
TABLE 389 POLAND BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 217
TABLE 390 POLAND MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 217
TABLE 391 POLAND MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 217
TABLE 392 POLAND PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 217
TABLE 393 POLAND OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 218
TABLE 394 POLAND CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 218
TABLE 395 POLAND STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 218
TABLE 396 POLAND COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 218
TABLE 397 POLAND HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 219
TABLE 398 POLAND OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 219
TABLE 399 POLAND CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 219
TABLE 400 POLAND CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 219
TABLE 401 POLAND CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 220
TABLE 402 POLAND PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 220
TABLE 403 HUNGARY CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 221
TABLE 404 HUNGARY CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 221
TABLE 405 HUNGARY CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 221
TABLE 406 HUNGARY CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 221
TABLE 407 HUNGARY MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 222
TABLE 408 HUNGARY MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 222
TABLE 409 HUNGARY MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 222
TABLE 410 HUNGARY VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 222
TABLE 411 HUNGARY VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 222
TABLE 412 HUNGARY VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 223
TABLE 413 HUNGARY CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 223
TABLE 414 HUNGARY CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 223
TABLE 415 HUNGARY CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 223
TABLE 416 HUNGARY IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 223
TABLE 417 HUNGARY IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 224
TABLE 418 HUNGARY IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 224
TABLE 419 HUNGARY CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 224
TABLE 420 HUNGARY LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 224
TABLE 421 HUNGARY BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 225
TABLE 422 HUNGARY MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 225
TABLE 423 HUNGARY MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 225
TABLE 424 HUNGARY PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 225
TABLE 425 HUNGARY OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 226
TABLE 426 HUNGARY CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 226
TABLE 427 HUNGARY STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 226
TABLE 428 HUNGARY COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 226
TABLE 429 HUNGARY HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 227
TABLE 430 HUNGARY OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 227
TABLE 431 HUNGARY CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 227
TABLE 432 HUNGARY CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 227
TABLE 433 HUNGARY CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 228
TABLE 434 HUNGARY PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 228
TABLE 435 LITHUANIA CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 229
TABLE 436 LITHUANIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 229
TABLE 437 LITHUANIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 229
TABLE 438 LITHUANIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 229
TABLE 439 LITHUANIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 230
TABLE 440 LITHUANIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 230
TABLE 441 LITHUANIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 230
TABLE 442 LITHUANIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 230
TABLE 443 LITHUANIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 230
TABLE 444 LITHUANIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 231
TABLE 445 LITHUANIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 231
TABLE 446 LITHUANIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 231
TABLE 447 LITHUANIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 231
TABLE 448 LITHUANIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 231
TABLE 449 LITHUANIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 232
TABLE 450 LITHUANIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 232
TABLE 451 LITHUANIA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 232
TABLE 452 LITHUANIA LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 232
TABLE 453 LITHUANIA BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 233
TABLE 454 LITHUANIA MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 233
TABLE 455 LITHUANIA MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 233
TABLE 456 LITHUANIA PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 233
TABLE 457 LITHUANIA OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 234
TABLE 458 LITHUANIA CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 234
TABLE 459 LITHUANIA STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 234
TABLE 460 LITHUANIA COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 234
TABLE 461 LITHUANIA HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 235
TABLE 462 LITHUANIA OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 235
TABLE 463 LITHUANIA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 235
TABLE 464 LITHUANIA CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 235
TABLE 465 LITHUANIA CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 236
TABLE 466 LITHUANIA PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 236
TABLE 467 AUSTRIA CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 237
TABLE 468 AUSTRIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 237
TABLE 469 AUSTRIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 237
TABLE 470 AUSTRIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 237
TABLE 471 AUSTRIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 238
TABLE 472 AUSTRIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 238
TABLE 473 AUSTRIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 238
TABLE 474 AUSTRIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 238
TABLE 475 AUSTRIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 238
TABLE 476 AUSTRIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 239
TABLE 477 AUSTRIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 239
TABLE 478 AUSTRIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 239
TABLE 479 AUSTRIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 239
TABLE 480 AUSTRIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 239
TABLE 481 AUSTRIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 240
TABLE 482 AUSTRIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 240
TABLE 483 AUSTRIA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 240
TABLE 484 AUSTRIA LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 240
TABLE 485 AUSTRIA BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 241
TABLE 486 AUSTRIA MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 241
TABLE 487 AUSTRIA MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 241
TABLE 488 AUSTRIA PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 241
TABLE 489 AUSTRIA OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 242
TABLE 490 AUSTRIA CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 242
TABLE 491 AUSTRIA STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 242
TABLE 492 AUSTRIA COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 242
TABLE 493 AUSTRIA HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 243
TABLE 494 AUSTRIA OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 243
TABLE 495 AUSTRIA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 243
TABLE 496 AUSTRIA CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 243
TABLE 497 AUSTRIA CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 244
TABLE 498 AUSTRIA PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 244
TABLE 499 IRELAND CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 245
TABLE 500 IRELAND CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 245
TABLE 501 IRELAND CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 245
TABLE 502 IRELAND CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 245
TABLE 503 IRELAND MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 246
TABLE 504 IRELAND MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 246
TABLE 505 IRELAND MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 246
TABLE 506 IRELAND VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 246
TABLE 507 IRELAND VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 246
TABLE 508 IRELAND VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 247
TABLE 509 IRELAND CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 247
TABLE 510 IRELAND CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 247
TABLE 511 IRELAND CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 247
TABLE 512 IRELAND IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 247
TABLE 513 IRELAND IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 248
TABLE 514 IRELAND IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 248
TABLE 515 IRELAND CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 248
TABLE 516 IRELAND LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 248
TABLE 517 IRELAND BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 249
TABLE 518 IRELAND MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 249
TABLE 519 IRELAND MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 249
TABLE 520 IRELAND PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 249
TABLE 521 IRELAND OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 250
TABLE 522 IRELAND CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 250
TABLE 523 IRELAND STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 250
TABLE 524 IRELAND COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 250
TABLE 525 IRELAND HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 251
TABLE 526 IRELAND OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 251
TABLE 527 IRELAND CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 251
TABLE 528 IRELAND CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 251
TABLE 529 IRELAND CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 252
TABLE 530 IRELAND PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 252
TABLE 531 NORWAY CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 253
TABLE 532 NORWAY CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 253
TABLE 533 NORWAY CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 253
TABLE 534 NORWAY CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 253
TABLE 535 NORWAY MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 254
TABLE 536 NORWAY MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 254
TABLE 537 NORWAY MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 254
TABLE 538 NORWAY VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 254
TABLE 539 NORWAY VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 254
TABLE 540 NORWAY VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 255
TABLE 541 NORWAY CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 255
TABLE 542 NORWAY CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 255
TABLE 543 NORWAY CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 255
TABLE 544 NORWAY IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 255
TABLE 545 NORWAY IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 256
TABLE 546 NORWAY IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 256
TABLE 547 NORWAY CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 256
TABLE 548 NORWAY LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 256
TABLE 549 NORWAY BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 257
TABLE 550 NORWAY MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 257
TABLE 551 NORWAY MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 257
TABLE 552 NORWAY PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 257
TABLE 553 NORWAY OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 258
TABLE 554 NORWAY CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 258
TABLE 555 NORWAY STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 258
TABLE 556 NORWAY COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 258
TABLE 557 NORWAY HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 259
TABLE 558 NORWAY OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 259
TABLE 559 NORWAY CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 259
TABLE 560 NORWAY CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 259
TABLE 561 NORWAY CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 260
TABLE 562 NORWAY PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 260
TABLE 563 REST OF EUROPE CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 261

LIST OF FIGURES

FIGURE 1 EUROPE CANCER IMMUNOTHERAPY MARKET: SEGMENTATION 45
FIGURE 2 EUROPE CANCER IMMUNOTHERAPY MARKET: DATA TRIANGULATION 48
FIGURE 3 EUROPE CANCER IMMUNOTHERAPY MARKET: DROC ANALYSIS 49
FIGURE 4 EUROPE CANCER IMMUNOTHERAPY MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 50
FIGURE 5 EUROPE CANCER IMMUNOTHERAPY MARKET: COMPANY RESEARCH ANALYSIS 50
FIGURE 6 EUROPE CANCER IMMUNOTHERAPY MARKET: INTERVIEW DEMOGRAPHICS 51
FIGURE 7 EUROPE CANCER IMMUNOTHERAPY MARKET: MARKET END USER COVERAGE GRID 53
FIGURE 8 EUROPE CANCER IMMUNOTHERAPY MARKET: DBMR MARKET POSITION GRID 54
FIGURE 9 EUROPE CANCER IMMUNOTHERAPY MARKET: VENDOR SHARE ANALYSIS 55
FIGURE 10 EUROPE CANCER IMMUNOTHERAPY MARKET: SEGMENTATION 58
FIGURE 11 RISING PREVALENCE OF CANCER AND RISING TECHNOLOGICAL ADVANCEMENTS ARE EXPECTED TO DRIVE THE GROWTH OF THE EUROPE CANCER IMMUNOTHERAPY MARKET FROM 2024 TO 2034 59
FIGURE 12 CHECKPOINT INHIBITORS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE CANCER CHEMOTHERAPY CONSUMABLES MARKET IN 2024 TO 2031 59
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE CANCER IMMUNOTHERAPY MARKET 71
FIGURE 14 EUROPE CANCER IMMUNOTHERAPYMARKET : BY PRODUCT TYPE, 2023 79
FIGURE 15 EUROPE CANCER IMMUNOTHERAPYMARKET : BY PRODUCT TYPE, 2024-2031 (USD MILLION) 80
FIGURE 16 EUROPE CANCER IMMUNOTHERAPYMARKET : BY PRODUCT TYPE, CAGR (2024-2031) 80
FIGURE 17 EUROPE CANCER IMMUNOTHERAPYMARKET : BY PRODUCT TYPE, LIFELINE CURVE 81
FIGURE 18 EUROPE CANCER IMMUNOTHERAPYMARKET : BY END USER, 2023 92
FIGURE 19 EUROPE CANCER IMMUNOTHERAPYMARKET : BY END USER, 2024-2031 (USD MILLION) 93
FIGURE 20 EUROPE CANCER IMMUNOTHERAPYMARKET : BY END USER, CAGR (2024-2031) 93
FIGURE 21 EUROPE CANCER IMMUNOTHERAPYMARKET : BY END USER, LIFELINE CURVE 94
FIGURE 22 EUROPE CANCER IMMUNOTHERAPY MARKET: BY DISTRIBUTION CHANNEL, 2023 99
FIGURE 23 EUROPE CANCER IMMUNOTHERAPY MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 100
FIGURE 24 EUROPE CANCER IMMUNOTHERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 100
FIGURE 25 EUROPE CANCER IMMUNOTHERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 101
FIGURE 26 EUROPE CANCER IMMUNOTHERAPY MARKET: BY FORM, 2023 106
FIGURE 27 EUROPE CANCER IMMUNOTHERAPY MARKET: BY FORM, 2024-2031 (USD MILLION) 107
FIGURE 28 EUROPE CANCER IMMUNOTHERAPY MARKET: BY FORM, CAGR (2024-2031) 107
FIGURE 29 EUROPE CANCER IMMUNOTHERAPY MARKET: BY FORM, LIFELINE CURVE 108
FIGURE 30 EUROPE CANCER IMMUNOTHERAPY MARKET: BY APPLICATION, 2023 112
FIGURE 31 EUROPE CANCER IMMUNOTHERAPY MARKET: BY APPLICATION, 2024-2031 (USD MILLION) 113
FIGURE 32 EUROPE CANCER IMMUNOTHERAPY MARKET: BY APPLICATION, CAGR (2024-2031) 113
FIGURE 33 EUROPE CANCER IMMUNOTHERAPY MARKET: BY APPLICATION, LIFELINE CURVE 114
FIGURE 34 EUROPE CANCER IMMUNOTHERAPY MARKET: SNAPSHOT (2023) 132
FIGURE 35 EUROPE CANCER IMMUNOTHERAPY MARKET: COMPANY SHARE 2023 (%) 262